EUVIMEDEUVIMED entdecken
Crossref

ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion

Shouyan Deng, Yibo Zhang, Huanbin Wang, Wenhua Liang, Lu Xie, Ning Li, Yuan Fang, Yiting Wang, Jiayang Liu, Hao Chi, Yufan Sun, Rui Ye und 10 weitere

Cell · 2024-04 · 187 (9) · 2305-2323.e33

DOI: 10.1016/j.cell.2024.03.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2024-04. Verfasst von Shouyan Deng und 21 weiteren Autor:innen. Beteiligte Einrichtung: Institutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism …. Hauptthemen laut MEDLINE: CD3 Complex, Lymphocyte Activation, T-Lymphocytes, Tumor Escape. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Science and Technology Innovation Plan Of Shanghai Science and Technology Commission, School of Medicine, Shanghai Jiao Tong University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy has transformed treatment possibilities, but its effectiveness differs significantly among patients, indicating the presence of alternative pathways for immune evasion. Here, we show that ITPRIPL1 functions as an inhibitory ligand of CD3ε, and its expression inhibits T cells in the tumor microenvironment. The binding of ITPRIPL1 extracellular domain to CD3ε on T cells significantly decreased calcium influx and ZAP70 phosphorylation, impeding initial T cell activation. Treatment with a neutralizing antibody against ITPRIPL1 restrained tumor growth and promoted T cell infiltration in mouse models across various solid tumor types. The antibody targeting canine ITPRIPL1 exhibited notable therapeutic efficacy against naturally occurring tumors in pet clinics. These findings highlight the role of ITPRIPL1 (or CD3L1, CD3ε ligand 1) in impeding T cell activation during the critical "signal one" phase. This discovery positions ITPRIPL1 as a promising therapeutic target against multiple tumor types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD3 ComplexLymphocyte ActivationT-LymphocytesTumor EscapeTumor MicroenvironmentAnimalsHumansMiceDogsNeoplasmsCell Line, TumorFemaleProtein BindingZAP-70 Protein-Tyrosine KinaseAntibodies, NeutralizingMice, Inbred C57BL

Stichwörter der Autor:innen

CD3εITPRIPL1cancer immunotherapyimmune checkpointimmune evasion

Substanzen

CD3 ComplexCD3E protein, humanZAP-70 Protein-Tyrosine KinaseAntibodies, Neutralizing

Autor:innen und Institutionen

  • Institutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Zhongshan-Xuhui Hospital, Fudan…
  • BioTroy Therapeutics, Shanghai 201400, China.
  • Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai 200031, China.
  • Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.
  • Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100020, China.
  • Department of Oncology, Shanghai Sixth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai 200233, China.

Förderung

  • Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
  • School of Medicine, Shanghai Jiao Tong University
  • National Natural Science Foundation of China
  • Fudan University

Zitieren

APA

Deng, S., Zhang, Y., Wang, H., Liang, W., Xie, L., Li, N., Fang, Y., Wang, Y., Liu, J., Chi, H., Sun, Y., Ye, R., Shan, L., Shi, J., Shen, Z., Wang, Y., Wang, S., Brosseau, J. P., Wang, F., …, & Xu, J. (2024). ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion. Cell, 187(9), 2305-2323.e33. https://doi.org/10.1016/j.cell.2024.03.019

Vancouver

Deng S, Zhang Y, Wang H, Liang W, Xie L, Li N, et al. ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion. Cell. 2024;187(9):2305-2323.e33. doi:10.1016/j.cell.2024.03.019

BibTeX
@article{Deng2024,
  author = {Deng, Shouyan and Zhang, Yibo and Wang, Huanbin and Liang, Wenhua and Xie, Lu and Li, Ning and Fang, Yuan and Wang, Yiting and Liu, Jiayang and Chi, Hao and Sun, Yufan and Ye, Rui and Shan, Lishen and Shi, Jiawei and Shen, Zan and Wang, Yonggang and Wang, Shuhang and Brosseau, Jean-Philippe and Wang, Feng and Liu, Grace and Quan, Yingfei and Xu, Jie},
  title = {ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {9},
  pages = {2305--2323.e33},
  doi = {10.1016/j.cell.2024.03.019}
}
Kostenlos starten →